Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Primary left atrial spindle cell sarcoma with low-grade malignant features mimicking recurrent myxoma: a case report.

Journal of cardiothoracic surgery·2026
Same author

Long-term pregnancy outcomes after deferential vessel‑sparing microsurgical vasoepididymostomy.

Translational andrology and urology·2026
Same author

Primary malignant cardiac tumor of the left atrium masqueraded as multiple myxomas.

Quantitative imaging in medicine and surgery·2026
Same author

[Advances in manufacturing measurement technology for 5-HMF formed during honey-refining process for large traditional Chinese medicine honeyed pills].

Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica·2026
Same author

[Identification of critical quality attributes related to property and flavor of Jianwei Xiaoshi Tablets based on T1R2/T1R3/TRPV1-HEMT biosensor].

Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica·2025
Same author

Rare Giant Cardiac Malignancy: Primary Cardiac Synovial Sarcoma.

Echocardiography (Mount Kisco, N.Y.)·2025

Related Experiment Video

Updated: May 30, 2026

Assessing Endothelial Vasodilator Function with the Endo-PAT 2000
07:46

Assessing Endothelial Vasodilator Function with the Endo-PAT 2000

Published on: October 15, 2010

[Smoking impairs endothelial function in ED patients].

Feng-juan Yao1, Yan-ping Huang, Hong Lin

  • 1Department of Ultrasound, The First Hospital Affiliated to Sun Yat-sen University, Guangzhou, Guangdong 510080, China.

Zhonghua Nan Ke Xue = National Journal of Andrology
|August 16, 2011
PubMed
Summary
This summary is machine-generated.

Smoking significantly impairs endothelial function in young erectile dysfunction (ED) patients. This damage is more pronounced in smokers compared to non-smokers, indicating a detrimental effect on vascular health.

More Related Videos

Assessment of Vascular Function in Patients With Chronic Kidney Disease
08:50

Assessment of Vascular Function in Patients With Chronic Kidney Disease

Published on: June 16, 2014

Fundus Photography as a Convenient Tool to Study Microvascular Responses to Cardiovascular Disease Risk Factors in Epidemiological Studies
10:11

Fundus Photography as a Convenient Tool to Study Microvascular Responses to Cardiovascular Disease Risk Factors in Epidemiological Studies

Published on: October 22, 2014

Related Experiment Videos

Last Updated: May 30, 2026

Assessing Endothelial Vasodilator Function with the Endo-PAT 2000
07:46

Assessing Endothelial Vasodilator Function with the Endo-PAT 2000

Published on: October 15, 2010

Assessment of Vascular Function in Patients With Chronic Kidney Disease
08:50

Assessment of Vascular Function in Patients With Chronic Kidney Disease

Published on: June 16, 2014

Fundus Photography as a Convenient Tool to Study Microvascular Responses to Cardiovascular Disease Risk Factors in Epidemiological Studies
10:11

Fundus Photography as a Convenient Tool to Study Microvascular Responses to Cardiovascular Disease Risk Factors in Epidemiological Studies

Published on: October 22, 2014

Area of Science:

  • Cardiovascular Science
  • Urology
  • Vascular Biology

Context:

  • Erectile dysfunction (ED) is increasingly recognized in younger populations.
  • Endothelial dysfunction is a potential underlying factor in ED.
  • The impact of smoking on endothelial function in young ED patients requires further elucidation.

Purpose:

  • To investigate the relationship between smoking and endothelial function in young men diagnosed with ED.
  • To compare endothelial function in ED patients (smokers vs. non-smokers) with healthy controls.

Summary:

  • A study involving 69 ED patients and 16 healthy controls measured brachial artery flow-mediated vasodilation (FMD).
  • ED patients exhibited significantly reduced FMD compared to controls.
  • Smokers with ED showed markedly lower FMD (6.0 ± 0.8%) than non-smokers with ED (9.7 ± 2.5%), highlighting smoking's adverse effect.

Impact:

  • Endothelial dysfunction is prevalent in young ED patients.
  • Smoking exacerbates endothelial dysfunction in this population.
  • Findings underscore the importance of smoking cessation for managing ED and cardiovascular risk.